{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:38:30Z","timestamp":1792175910661,"version":"4.4.0"},"reference-count":159,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"the Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"crossref","award":["420264\/2018-3"],"award-info":[{"award-number":["420264\/2018-3"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Minist\u00e9rio da Sa\u00fade (MS), and Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro","award":["SEI260003\/001147\/2020"],"award-info":[{"award-number":["SEI260003\/001147\/2020"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Breast cancer remains the most frequently diagnosed malignancy worldwide. Over the past decade, advances in molecular biology have expanded beyond tumor-intrinsic features to encompass the immune microenvironment and patient-specific pharmacogenomic profiles, profoundly reshaping diagnostic, prognostic, and therapeutic paradigms in breast oncology. Owing to rapid technological progress and an expanding therapeutic armamentarium, periodic synthesis of both foundational principles and emerging evidence remains essential for the critical interpretation of ongoing advances. This review provides a comprehensive overview of the contemporary global landscape of breast cancer, integrating developments in diagnosis, risk stratification, and therapeutic innovation. We examine the emerging technologies that are redefining tumor characterization, including digital pathology, artificial intelligence-assisted morphological and molecular analyses, and advanced molecular profiling approaches that increasingly inform prognostic and predictive assessment. We further discuss how these diagnostic frameworks are translating into therapeutic advances, with emphasis on immunotherapy, antibody-drug conjugates, mutation-directed targeted agents, therapeutic vaccines, and bispecific antibodies. Collectively, these developments highlight key translational research priorities, support evidence-based clinical decision-making, and explicitly acknowledge disparities in access and implementation between high-income settings and low- and middle-income countries (LMICs).<\/jats:p>","DOI":"10.3390\/ijms27041902","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T12:37:28Z","timestamp":1771245448000},"page":"1902","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advances in Breast Cancer Research: Immunological, Pathological, and Pharmacological Perspectives for Improving Patient Outcomes"],"prefix":"10.3390","volume":"27","author":[{"given":"Susanne","family":"Crocamo","sequence":"first","affiliation":[{"name":"Instituto Nacional de Cancer, Rio de Janeiro 20560120, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3412-5325","authenticated-orcid":false,"given":"Everton Cruz","family":"dos Santos","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Cancer, Rio de Janeiro 20560120, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5166-0832","authenticated-orcid":false,"given":"Eliana","family":"Abdelhay","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Cancer, Rio de Janeiro 20560120, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1172\/JCI60534","article-title":"Heterogeneity in Breast Cancer","volume":"121","author":"Polyak","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature17676","article-title":"Landscape of Somatic Mutations in 560 Breast Cancer Whole-Genome Sequences","volume":"534","author":"Davies","year":"2016","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000350774","article-title":"A Brief Overview of the WHO Classification of Breast Tumors, 4th Edition, Focusing on Issues and Updates from the 3rd Edition","volume":"8","author":"Sinn","year":"2013","journal-title":"Breast Care"},{"key":"ref_4","first-page":"229","article-title":"Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s10549-010-0746-x","article-title":"Combinatorial Biomarker Expression in Breast Cancer","volume":"120","author":"Rakha","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/14737159.2025.2482639","article-title":"Multi-Omic Profiling in Breast Cancer: Utility for Advancing Diagnostics and Clinical Care","volume":"25","author":"Parker","year":"2025","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5614","DOI":"10.62347\/MWNZ5609","article-title":"Advancing Precision and Personalized Breast Cancer Treatment through Multi-Omics Technologies","volume":"14","author":"Zhang","year":"2024","journal-title":"Am. J. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","article-title":"Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes","volume":"27","author":"Parker","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"8418","DOI":"10.1073\/pnas.0932692100","article-title":"Repeated Observation of Breast Tumor Subtypes in Independent Gene Expression Data Sets","volume":"100","author":"Tibshirani","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nm.3886","article-title":"Subclonal Diversification of Primary Breast Cancer Revealed by Multiregion Sequencing","volume":"21","author":"Yates","year":"2015","journal-title":"Nat. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"366","DOI":"10.4048\/jbc.2022.25.e30","article-title":"Clinical Application of Next-Generation Sequencing in Patients with Breast Cancer: Real-World Data","volume":"25","author":"Suh","year":"2022","journal-title":"J. Breast Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2\/Neu Oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1158\/1078-0432.CCR-15-1555","article-title":"Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer","volume":"22","author":"Liu","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"38299","DOI":"10.1038\/s41598-025-22202-z","article-title":"Adaptive Multi-Omics Integration Framework for Breast Cancer Survival Analysis","volume":"15","author":"Hasanzadeh","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Malighetti, F., Villa, M., Villa, A.M., Pelucchi, S., Aroldi, A., Cortinovis, D.L., Canova, S., Capici, S., Cazzaniga, M.E., and Mologni, L. (2025). Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26051943"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41389-024-00521-6","article-title":"Comprehensive Multi-Omics Analysis of Breast Cancer Reveals Distinct Long-Term Prognostic Subtypes","volume":"13","author":"Sharma","year":"2024","journal-title":"Oncogenesis"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejca.2009.09.009","article-title":"ONCOPOOL\u2014A European Database for 16,944 Cases of Breast Cancer","volume":"46","author":"Blamey","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"ref_18","first-page":"765","article-title":"Bc-GenExMiner: An Easy-To-Use Online Platform for Gene Prognostic Analyses in Breast Cancer","volume":"131","author":"Campone","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1093\/ije\/dyab139","article-title":"Data Resource Profile: Breast Cancer Data Base Sweden 2.0 (BCBaSe 2.0)","volume":"50","author":"Wadsten","year":"2022","journal-title":"Int. J. Epidemiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"A68","DOI":"10.5114\/wo.2014.47136","article-title":"Review the Cancer Genome Atlas (TCGA): An Immeasurable Source of Knowledge","volume":"19","author":"Tomczak","year":"2015","journal-title":"Wsp\u00f3\u0142czesna Onkol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature10983","article-title":"The Genomic and Transcriptomic Architecture of 2000 Breast Tumours Reveals Novel Subgroups","volume":"486","author":"Curtis","year":"2012","journal-title":"Nature"},{"key":"ref_22","first-page":"1","article-title":"Big Data in Breast Cancer: Towards Precision Treatment","volume":"10","author":"Zhang","year":"2024","journal-title":"Digit. Health"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive Molecular Portraits of Human Breast Tumours","volume":"490","author":"Koboldt","year":"2012","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and Validation of a Clinical Cancer Genomic Profiling Test Based on Massively Parallel DNA Sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer","volume":"375","author":"Cardoso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10549-016-3725-z","article-title":"Prognostic Ability of EndoPredict Compared to Research-Based Versions of the PAM50 Risk of Recurrence (ROR) Scores in Node-Positive, Estrogen Receptor-Positive, and HER2-Negative Breast Cancer. A GEICAM\/9906 Sub-Study","volume":"156","author":"Martin","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"102498","DOI":"10.1016\/j.ctrv.2022.102498","article-title":"Artificial Intelligence in Cancer Research and Precision Medicine: Applications, Limitations and Priorities to Drive Transformation in the Delivery of Equitable and Unbiased Care","volume":"112","author":"Corti","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Khare, P.S., Shaikh, S.A., and Havelikar, U. Artificial Intelligence and Precision Medicine for Optimizing Patient Care: A Comprehensive Review. Intell. Hosp., 2025, 100042.","DOI":"10.1016\/j.inhs.2025.100042"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-Infiltrating Lymphocytes and Prognosis in Different Subtypes of Breast Cancer: A Pooled Analysis of 3771 Patients Treated with Neoadjuvant Therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1158\/1078-0432.CCR-10-0505","article-title":"Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells","volume":"16","author":"Vonderheide","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5729","DOI":"10.1158\/1078-0432.CCR-16-0190","article-title":"A Pilot Study of Preoperative Single-Dose Ipilimumab And\/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling","volume":"22","author":"McArthur","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1158\/1078-0432.CCR-21-2182","article-title":"A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609)","volume":"28","author":"Adams","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e008872\u201311","DOI":"10.1136\/jitc-2024-008872","article-title":"Randomized, Open-Label, Phase 2 Study of Nivolumab plus Ipilimumab or Nivolumab Monotherapy in Patients with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden","volume":"12","author":"Schenker","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus Nab-Paclitaxel as First-Line Treatment for Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer (IMpassion130): Updated Efficacy Results from a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/jnci\/djab004","article-title":"Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study","volume":"113","author":"Emens","year":"2021","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.annonc.2022.07.1940","article-title":"Neoadjuvant Durvalumab Improves Survival in Early Triple-Negative Breast Cancer Independent of Pathological Complete Response","volume":"33","author":"Loibl","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41591-023-02677-x","article-title":"Toripalimab plus Nab-Paclitaxel in Metastatic or Recurrent Triple-Negative Breast Cancer: A Randomized Phase 3 Trial","volume":"30","author":"Jiang","year":"2024","journal-title":"Nat. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1158\/2767-9764.CRC-22-0486","article-title":"Phase I Trial of Autologous RNA-Electroporated CMET-Directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma","volume":"3","author":"Shah","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4248","DOI":"10.1158\/1078-0432.CCR-18-2867","article-title":"Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial","volume":"25","author":"Mittendorf","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Maeng, H.M., Moore, B.N., Bagheri, H., Steinberg, S.M., Inglefield, J., Dunham, K., Wei, W.-Z., Morris, J.C., Terabe, M., and England, L.C. (2021). Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine against HER2 Shows Safety and Preliminary Clinical Efficacy. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.789078"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1158\/1078-0432.CCR-21-2827","article-title":"First-In-Human HER2-Targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer: Results from a Phase I Study","volume":"28","author":"Zhang","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1158\/1078-0432.CCR-05-2436","article-title":"Phase I Trial of the Trifunctional Anti-HER2 X Anti-CD3 Antibody Ertumaxomab in Metastatic Breast Cancer","volume":"12","author":"Kiewe","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results from DESTINY-Breast03, a Randomised, Open-Label, Phase 3 Trial","volume":"401","author":"Hurvitz","year":"2022","journal-title":"Lancet"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1056\/NEJMoa2508668","article-title":"Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer","volume":"394","author":"Tolaney","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Loibl, S., Park, Y.H., Shao, Z., Huang, C.-S., Barrios, C., Abraham, J., Prat, A., Niikura, N., Im, S.-A., and Li, W. (2025). Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer. N. Engl. J. Med., Online ahead of print.","DOI":"10.1056\/NEJMoa2514661"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","article-title":"Trastuzumab Deruxtecan in HER2-Positive Advanced Breast Cancer with or without Brain Metastases: A Phase 3b\/4 Trial","volume":"30","author":"Harbeck","year":"2024","journal-title":"Nat. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/JCO.24.00529","article-title":"Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2\u2013Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)","volume":"43","author":"Turner","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41392-025-02149-3","article-title":"ACE-Breast-02: A Randomized Phase III Trial of ARX788 versus Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer","volume":"10","author":"Hu","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S1470-2045(25)00470-X","article-title":"Patritumab Deruxtecan (HER3-DXd) in Patients with Active Brain Metastases of Breast Cancer (TUXEDO-3): A Multicentre, Single-Arm, Phase 2 Trial","volume":"26","author":"Bartsch","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa2511734","article-title":"Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer","volume":"393","author":"Punie","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa2508959","article-title":"Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer","volume":"394","author":"Tolaney","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.24.00920","article-title":"Datopotamab Deruxtecan versus Chemotherapy in Previously Treated Inoperable\/Metastatic Hormone Receptor\u2013Positive Human Epidermal Growth Factor Receptor 2\u2013Negative Breast Cancer: Primary Results from TROPION-Breast01","volume":"43","author":"Bardia","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1158\/1078-0432.CCR-17-2092","article-title":"Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer","volume":"24","author":"Rossi","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1158\/1078-0432.CCR-18-3663","article-title":"Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence","volume":"25","author":"Coombes","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41698-025-00876-y","article-title":"Circulating Tumor DNA to Monitor Treatment Response in Solid Tumors and Advance Precision Oncology","volume":"9","author":"Bartolomucci","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"ref_63","first-page":"302ra133","article-title":"Mutation Tracking in Circulating Tumor DNA Predicts Relapse in Early Breast Cancer","volume":"7","author":"Schiavon","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ijc.34945","article-title":"Clinical Efficacy of Tumor Organoid-Guided Cancer Therapy for Locally Advanced Unresectable or Metastatic Breast Cancer","volume":"155","author":"Lin","year":"2024","journal-title":"Int. J. Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2400015","DOI":"10.1002\/nano.202400015","article-title":"Advances in Breast Cancer Research Using CRISPR\/Cas9 System","volume":"5","author":"Eskandari","year":"2024","journal-title":"Nano Sel."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"eaba7365","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-Engineered T Cells in Patients with Refractory Cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Li, J., Qiu, J., Han, J., Li, X., and Jiang, Y. (2022). Tumor Microenvironment Characterization in Breast Cancer Identifies Prognostic Pathway Signatures. Genes, 13.","DOI":"10.3390\/genes13111976"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"11149","DOI":"10.1002\/cam4.5698","article-title":"Role of Tumor Microenvironment in Cancer Progression and Therapeutic Strategy","volume":"12","author":"Wang","year":"2023","journal-title":"Cancer Med."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Salemme, V., Centonze, G., Cavallo, F., Defilippi, P., and Conti, L. (2021). The Crosstalk between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.610303"},{"key":"ref_71","unstructured":"(2026, January 06). Avastin|European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/avastin#news-on."},{"key":"ref_72","unstructured":"(2026, January 06). Avastin\u00ae (Bevacizumabe): O Medicamento Deve Ser Prescrito para o Tratamento de C\u00e2ncer de Mama Metast\u00e1tico Somente em Combina\u00e7\u00e3o com o Paclitaxel.\u2014Listagem de Alertas\u2014Anvisa, Available online: https:\/\/antigo.anvisa.gov.br\/listagem-de-alertas\/-\/asset_publisher\/R6VaZWsQDDzS\/content\/avastin-bevacizumabe-o-medicamento-deve-ser-prescrito-para-o-tratamento-de-cancer-de-mama-metastatico-somente-em-combinacao-com-o-paclitaxel-\/33868?inheritRedirect=false."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1093\/annonc\/mdu112","article-title":"Tumor Infiltrating Lymphocytes Are Prognostic in Triple Negative Breast Cancer and Predictive for Trastuzumab Benefit in Early Breast Cancer: Results from the FinHER Trial","volume":"25","author":"Loi","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The Evaluation of Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer: Recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1093\/annonc\/mdv395","article-title":"Immune Modulation of Pathologic Complete Response after Neoadjuvant HER2-Directed Therapies in the NeoSphere Trial","volume":"26","author":"Bianchini","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10549-019-05272-2","article-title":"Prognostic Role of Immune Infiltrates in Breast Ductal Carcinoma in Situ","volume":"177","author":"Chen","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/jnci\/djy076","article-title":"Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab\/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy","volume":"111","author":"Ignatiadis","year":"2018","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1007\/s12094-023-03080-1","article-title":"The Prognostic Values of FOXP3+ Tumor-Infiltrating T Cells in Breast Cancer: A Systematic Review and Meta-Analysis","volume":"25","author":"Sun","year":"2023","journal-title":"Clin. Transl. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41523-024-00636-4","article-title":"Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy and Dual HER2-Blockade","volume":"10","author":"Liefaard","year":"2024","journal-title":"npj Breast Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"104120","DOI":"10.1016\/j.esmoop.2024.104120","article-title":"Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancer: Potential Impact and Challenges","volume":"10","author":"Schlam","year":"2025","journal-title":"ESMO Open"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1200\/JCO.18.01010","article-title":"Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers","volume":"37","author":"Loi","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/pin.12355","article-title":"Defining Lymphocyte-Predominant Breast Cancer by the Proportion of Lymphocyte-Rich Stroma and Its Significance in Routine Histopathological Diagnosis","volume":"65","author":"Ohtani","year":"2015","journal-title":"Pathol. Int."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e2200317","DOI":"10.1200\/PO.22.00317","article-title":"Association between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients with Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis","volume":"7","author":"Loi","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Ciarka, A., Pi\u0105tek, M., P\u0119ksa, R., Kunc, M., and Senkus, E. (2024). Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer: Prognostic and Predictive Significance across Molecular Subtypes. Biomedicines, 12.","DOI":"10.3390\/biomedicines12040763"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/nrclinonc.2015.215","article-title":"Clinical Relevance of Host Immunity in Breast Cancer: From TILs to the Clinic","volume":"13","author":"Savas","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-018-0040-8","article-title":"Immune Recognition of Somatic Mutations Leading to Complete Durable Regression in Metastatic Breast Cancer","volume":"24","author":"Zacharakis","year":"2018","journal-title":"Nat. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/annonc\/mdx308","article-title":"De-Escalating and Escalating Treatments for Early-Stage Breast Cancer: The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017","volume":"28","author":"Curigliano","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early Breast Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory Mechanisms of PD-1\/PD-L1 in Cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: A Moving Target in Immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for Early Triple-Negative Breast Cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s12672-025-04195-3","article-title":"Advancing Breast Cancer Treatment through Dual Targeting CAR T Cell Therapy","volume":"17","author":"Sheikh","year":"2025","journal-title":"Discov. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","article-title":"CAR-T Therapy in Solid Tumors","volume":"43","author":"Du","year":"2025","journal-title":"Cancer Cell"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s12935-025-03938-0","article-title":"Advancements and Challenges in CAR-T Cell Therapy for Solid Tumors: A Comprehensive Review of Antigen Targets, Strategies, and Future Directions","volume":"25","author":"Zhu","year":"2025","journal-title":"Cancer Cell Int."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12935-024-03615-8","article-title":"Current Status and Innovative Developments of CAR-T-Cell Therapy for the Treatment of Breast Cancer","volume":"25","author":"Marei","year":"2025","journal-title":"Cancer Cell Int."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1158\/2326-6066.CIR-17-0189","article-title":"Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer","volume":"5","author":"Tchou","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_97","first-page":"503","article-title":"Phase I Study of ROR1 Specific CAR T Cells in Advanced Hematopoietic and Epithelial Malignancies","volume":"31","author":"Specht","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of Chimeric Antigen Receptor T Cells: Recognition and Management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.7150\/ijbs.70120","article-title":"CAR-T Cell Therapy for Breast Cancer: From Basic Research to Clinical Application","volume":"18","author":"Yang","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Zhu, S.-Y., and Yu, K.-D. (2022). Breast Cancer Vaccines: Disappointing or Promising?. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.828386"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Nordin, M.L., Azemi, A.K., Nordin, A.H., Nabgan, W., Ng, P.Y., Yusoff, K., Abu, N., Lim, K.P., Zakaria, Z.A., and Ismail, N. (2023). Peptide-Based Vaccine against Breast Cancer: Recent Advances and Prospects. Pharmaceuticals, 16.","DOI":"10.3390\/ph16070923"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00262-010-0869-2","article-title":"Anti-HER2 Vaccines: New Prospects for Breast Cancer Therapy","volume":"59","author":"Ladjemi","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"h988","DOI":"10.1136\/bmj.h988","article-title":"Cancer Vaccines","volume":"350","author":"Butterfield","year":"2015","journal-title":"BMJ"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/11313490-000000000-00000","article-title":"Therapeutic Breast Cancer Vaccines","volume":"23","author":"Shumway","year":"2009","journal-title":"BioDrugs"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1002\/ijc.31551","article-title":"Developing Anti-HER2 Vaccines: Breast Cancer Experience","volume":"143","author":"Ibrahim","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1002\/eji.201343324","article-title":"Dendritic Cells Process Synthetic Long Peptides Better than Whole Protein, Improving Antigen Presentation and T-Cell Activation","volume":"43","author":"Rosalia","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2217\/imt.14.22","article-title":"The HER2 Peptide Nelipepimut-S (E75) Vaccine (NeuVaxTM) in Breast Cancer Patients at Risk for Recurrence: Correlation of Immunologic Data with Clinical Response","volume":"6","author":"Schneble","year":"2014","journal-title":"Immunotherapy"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Lamberti, M.J., Nigro, A., Mentucci, F.M., Vittar, N.B.R., Casolaro, V., and Col, J.D. (2020). Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12030256"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Bernal-Est\u00e9vez, D.A., Ort\u00edz Barbosa, M.A., Ort\u00edz-Montero, P., Cifuentes, C., S\u00e1nchez, R., and Parra-L\u00f3pez, C.A. (2021). Autologous Dendritic Cells in Combination with Chemotherapy Restore Responsiveness of T Cells in Breast Cancer Patients: A Single-Arm Phase I\/II Trial. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.669965"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/17588359211064653","article-title":"Final Results Regarding the Addition of Dendritic Cell Vaccines to Neoadjuvant Chemotherapy in Early HER2-Negative Breast Cancer Patients: Clinical and Translational Analysis","volume":"13","author":"Santisteban","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1111\/bcp.13947","article-title":"Assessing the Impact of the Addition of Dendritic Cell Vaccination to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Model-Based Characterization Approach","volume":"85","author":"Solans","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Kodumudi, K.N., Ramamoorthi, G., Snyder, C., Basu, A., Jia, Y., Awshah, S., Beyer, A.P., Wiener, D., Lam, L., and Zhang, H. (2019). Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01939"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1158\/1078-0432.CCR-16-1924","article-title":"Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2pos DCIS Independent of Route: Results of Randomized Selection Design Trial","volume":"23","author":"Lowenfeld","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e1207032","DOI":"10.1080\/2162402X.2016.1207032","article-title":"Addition of Anti-Estrogen Therapy to Anti-HER2 Dendritic Cell Vaccination Improves Regional Nodal Immune Response and Pathologic Complete Response Rate in Patients with ERpos\/HER2posEarly Breast Cancer","volume":"6","author":"Lowenfeld","year":"2016","journal-title":"OncoImmunology"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Mej\u00edas Sosa, L., L\u00f3pez-Janeiro, \u00c1., C\u00f3rdoba Iturriagagoitia, A., Sala, P., Solans, B.P., Hato, L., Inog\u00e9s, S., L\u00f3pez-D\u00edaz de Cerio, A., Guill\u00e9n-Grima, F., and Espin\u00f3s, J. (2023). Modification of Breast Cancer Milieu with Chemotherapy plus Dendritic Cell Vaccine: An Approach to Select Best Therapeutic Strategies. Biomedicines, 11.","DOI":"10.3390\/biomedicines11020238"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"114685","DOI":"10.1016\/j.biopha.2023.114685","article-title":"Dendritic Cell Vaccines in Breast Cancer: Immune Modulation and Immunotherapy","volume":"162","author":"Qian","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1023\/A:1018576224062","article-title":"Specificities of Anti-Sialyl-Tn and Anti-Tn Monoclonal Antibodies Generated Using Novel Clustered Synthetic Glycopeptide Epitopes","volume":"14","author":"Reddish","year":"1997","journal-title":"Glycoconj. J."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"577","DOI":"10.7150\/jca.7028","article-title":"Survival Advantage in Patients with Metastatic Breast Cancer Receiving Endocrine Therapy plus Sialyl Tn-KLH Vaccine: Post Hoc Analysis of a Large Randomized Trial","volume":"4","author":"Ibrahim","year":"2013","journal-title":"J. Cancer"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"MRNA Vaccines\u2014A New Era in Vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Li, R.Q., Wang, W., Yan, L., Song, L.Y., Guan, X., Zhang, W., and Lian, J. (2022). Identification of Tumor Antigens and Immune Subtypes in Breast Cancer for MRNA Vaccine Development. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.973712"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s12672-025-02542-y","article-title":"Advances in MRNA Vaccine Therapy for Breast Cancer Research","volume":"16","author":"Li","year":"2025","journal-title":"Discov. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"110832","DOI":"10.1016\/j.humimm.2024.110832","article-title":"Novel HER2-Based Multi-Epitope Vaccine (HER2-MEV) against HER2-Positive Breast Cancer: In Silico Design and Validation","volume":"85","author":"Seadawy","year":"2024","journal-title":"Hum. Immunol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13073-024-01388-3","article-title":"Neoantigen DNA Vaccines Are Safe, Feasible, and Induce Neoantigen-Specific Immune Responses in Triple-Negative Breast Cancer Patients","volume":"16","author":"Zhang","year":"2024","journal-title":"Genome Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.vaccine.2023.02.048","article-title":"In Silico Designed MRNA Vaccines Targeting CA-125 Neoantigen in Breast and Ovarian Cancer","volume":"41","author":"Lu","year":"2023","journal-title":"Vaccine"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Shariati, A., Khezrpour, A., Shariati, F., Afkhami, H., Yarahmadi, A., Alavimanesh, S., Kamrani, S., Modarressi, M.H., and Khani, P. (2025). DNA Vaccines as Promising Immuno-Therapeutics against Cancer: A New Insight. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1498431"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Brogna, M.R., Ferrara, G., Varone, V., Montone, A., Fava, A., Schiano, M.R., DelSesto, M., Pizza, N., Prota, A., and Barra, C. (2026). Bispecific Antibodies in Breast Cancer Immunotherapy: Mechanisms, Advances, and Translational Challenges. Target. Oncol.","DOI":"10.1007\/s11523-026-01198-0"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Abdeldaim, D.T., and Schindowski, K. (2023). Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15102402"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Lan, H.-R., Chen, M., Yao, S.-Y., Chen, J.-X., and Jin, K.-T. (2023). Bispecific Antibodies Revolutionizing Breast Cancer Treatment: A Comprehensive Overview. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1266450"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1089\/scd.1.1995.4.415","article-title":"G-CSF-Stimulated PMN in Immunotherapy of Breast Cancer with a Bispecific Antibody to Fc\u03b3RI and to HER-2\/Neu (MDX-210)","volume":"4","author":"Repp","year":"1995","journal-title":"J. Hematotherapy"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s002620050543","article-title":"A Phase I Study of a HER2\/Neu Bispecific Antibody with Granulocyte-Colony-Stimulating Factor in Patients with Metastatic Breast Cancer That Overexpresses HER2\/Neu","volume":"48","author":"Pullarkat","year":"1999","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.micinf.2010.10.020","article-title":"Brucella Abortus Inhibits IFN-\u03b3-Induced Fc\u03b3RI Expression and Fc\u03b3RI-Restricted Phagocytosis via Toll-like Receptor 2 on Human Monocytes\/Macrophages","volume":"13","author":"Barrionuevo","year":"2011","journal-title":"Microbes Infect."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/sj.leu.2402424","article-title":"Analysis of CD20-Dependent Cellular Cytotoxicity by G-CSF-Stimulated Neutrophils","volume":"16","author":"Baars","year":"2002","journal-title":"Leukemia"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejca.2020.11.045","article-title":"CDK12 Inhibition Enhances Sensitivity of HER2+ Breast Cancers to HER2-Tyrosine Kinase Inhibitor via Suppressing PI3K\/AKT","volume":"145","author":"Li","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1158\/1078-0432.CCR-14-2280","article-title":"Targeted T-Cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial","volume":"21","author":"Lum","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"e002194","DOI":"10.1136\/jitc-2020-002194","article-title":"Phase II Clinical Trial Using Anti-CD3 \u00d7 Anti-HER2 Bispecific Antibody Armed Activated T Cells (HER2 BATs) Consolidation Therapy for HER2 Negative (0\u20132+) Metastatic Breast Cancer","volume":"9","author":"Lum","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1002\/jcph.981","article-title":"Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future","volume":"57","author":"Vezina","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1016\/j.apsb.2021.05.024","article-title":"Target-Responsive Subcellular Catabolism Analysis for Early-Stage Antibody-Drug Conjugates Screening and Assessment","volume":"11","author":"Sang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody\u2013Drug Conjugates Come of Age in Oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Shi, R., Jia, L., Lv, Z., and Cui, J. (2025). Another Power of Antibody-Drug Conjugates: Immunomodulatory Effect and Clinical Applications. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1632705"},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Wang, Y., Lu, K., Xu, Y., Xu, S., Chu, H., and Fang, X. (2025). Antibody-Drug Conjugates as Immuno-Oncology Agents in Colorectal Cancer: Targets, Payloads, and Therapeutic Synergies. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1678907"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next Generation of Antibody\u2013Drug Conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"103012","DOI":"10.1016\/j.ctrv.2025.103012","article-title":"Combining Antibody-Drug Conjugates with Immune Checkpoint Inhibitors: A New Paradigm for Breast Cancer Therapy","volume":"140","author":"Xu","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-023-01509-2","article-title":"The Promise and Challenges of Combination Therapies with Antibody-Drug Conjugates in Solid Tumors","volume":"17","author":"Wei","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1056\/NEJMoa2406070","article-title":"Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer","volume":"392","author":"Geyer","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall Survival with Sacituzumab Govitecan in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer (TROPiCS-02): A Randomised, Open-Label, Multicentre, Phase 3 Trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"ref_146","first-page":"93","article-title":"Advances in Breast Cancer Care: The Role of Artificial Intelligence and Digital Pathology in Precision Medicine","volume":"21","year":"2025","journal-title":"Eur. J. Breast Health"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/15330338231169603","article-title":"Comparison between Manual and Automated Assessment of Ki-67 in Breast Carcinoma: Test of a Simple Method in Daily Practice","volume":"22","author":"Catteau","year":"2023","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10549-024-07256-3","article-title":"Immunohistochemical Assessment of HER2 Low Breast Cancer: Interobserver Reproducibility and Correlation with Digital Image Analysis","volume":"205","author":"Sun","year":"2024","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"29289","DOI":"10.1038\/s41598-025-13820-8","article-title":"AI Microscope Facilitates Accurate Interpretation of HER2 Immunohistochemical Scores 0 and 1+\u2009in Invasive Breast Cancer","volume":"15","author":"La","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"100416","DOI":"10.1016\/j.modpat.2023.100416","article-title":"Artificial Intelligence-Based Mitosis Scoring in Breast Cancer: Clinical Application","volume":"37","author":"Ibrahim","year":"2024","journal-title":"Mod. Pathol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"100921","DOI":"10.1016\/j.landig.2025.100921","article-title":"Label-Efficient Computational Tumour Infiltrating Lymphocyte Assessment in Breast Cancer (ECTIL): Multicentre Validation in 2340 Patients with Breast Cancer","volume":"7","author":"Schirris","year":"2025","journal-title":"Lancet Digit. Health"},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Rasic, D., Stovgaard, E.I.S., Jylling, A.M.B., Salgado, R., Hartman, J., Rantalainen, M., and L\u00e6nkholm, A.-V. (2025). AI Assessment of Tumor-Infiltrating Lymphocytes on Routine H&E-Slides as a Predictor of Response to Neoadjuvant Therapy in Breast Cancer-a Real-World Study. Virchows Arch.","DOI":"10.1007\/s00428-025-04283-3"},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Boisson, A., No\u00ebl, G., Saiselet, M., Rodrigues-Vit\u00f3ria, J., Thomas, N., Fontsa, M.L., Sofronii, D., Naveaux, C., Duvillier, H., and Craciun, L. (2021). Fluorescent Multiplex Immunohistochemistry Coupled with Other State-Of-The-Art Techniques to Systematically Characterize the Tumor Immune Microenvironment. Front. Mol. Biosci., 8.","DOI":"10.3389\/fmolb.2021.673042"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Parra, E.R. (2021). Methods to Determine and Analyze the Cellular Spatial Distribution Extracted from Multiplex Immunofluorescence Data to Understand the Tumor Microenvironment. Front. Mol. Biosci., 8.","DOI":"10.3389\/fmolb.2021.668340"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"100454","DOI":"10.1016\/j.jpi.2025.100454","article-title":"Advancing Open-Source Visual Analytics in Digital Pathology: A Systematic Review of Tools, Trends, and Clinical Applications","volume":"18","author":"Ahmad","year":"2025","journal-title":"J. Pathol. Inform."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/s41416-020-01122-x","article-title":"Deep Learning in Cancer Pathology: A New Generation of Clinical Biomarkers","volume":"124","author":"Echle","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41592-019-0540-6","article-title":"A Dream of Single-Cell Proteomics","volume":"16","author":"Marx","year":"2019","journal-title":"Nat. Methods"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/s12943-025-02450-3","article-title":"Artificial Intelligence in Cancer: Applications, Challenges, and Future Perspectives","volume":"24","author":"Cheng","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"9993","DOI":"10.1038\/s41467-024-54444-2","article-title":"An Umbrella Review of Socioeconomic Status and Cancer","volume":"15","author":"Li","year":"2024","journal-title":"Nat. Commun."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/4\/1902\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T05:16:22Z","timestamp":1771391782000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/4\/1902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":159,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["ijms27041902"],"URL":"https:\/\/doi.org\/10.3390\/ijms27041902","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]}}}